GU Cancers 2021 | KEYNOTE-057: extended follow-up of pembrolizumab in bladder cancer
Arjun Balar, MD, NYU Langone Health Perlmutter Cancer Center, New York City, NY, discusses extended follow-up results of cohort A from the Phase II KEYNOTE-057 study (NCT02625961) investigating pembrolizumab for the treatment of patients with high-risk non-muscle-invasive bladder cancer (NMIBC). 96 patients who were treated with pembrolizumab were included in the efficacy analysis. At a median follow-up of 36.4 months, the complete response rate was 40.6% and the median duration or response was 16.2 months. This interview took place during the 2021 Genitourinary Cancers Symposium.
Disclosures
Dr Arjun Balar, MD, has received consultancy fees from Genentech, Incyte, Janssen, Merck, Pfizer, AstraZeneca/Medimmune, Nektar, Seattle Genetics and Immunomedics; has received fees for contracted research from Genentech, Merck, AstraZeneca/Medimmune, Nektar, Seattle Genetics and Immunomedics; has participated in speaking engagements for Genentech, Merck and AstraZeneca/Medimmune; has participated in steering committees with Merck and Nektar; and has equity and is a member of the scientific advisory board of EpiVax Oncology.
